Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

AI-enabled clinical decision support in breast cancer care: a blinded multicenter benchmarking study comparing medically specialized with a general-purpose system.

Journal of medical systems·2026
Same author

Physicians' attitudes and perceived diagnostic confidence in point-of-care ultrasound in gynecology and obstetrics (GO-POCUS): a prospective single-center implementation study with structured training.

BMC medical education·2026
Same author

Spatial proteomics profiling reveals oncogene-specific immune niches and prognostic markers in NSCLC.

American journal of respiratory and critical care medicine·2026
Same author

Pulmonary Immune Cell Landscape Altered by Exposure to HIV, <i>Schistosoma</i> and Their Combination.

International journal of molecular sciences·2026
Same author

Machine Learning-Driven Drug Repurposing for KRAS G12C and KRAS G12D Inhibition.

ACS omega·2026
Same author

Variant-Specific Landscape of Mutual Exclusivity Among BRAF, EGFR, and KRAS Oncogenes Reveals Overlap With Functionally Antagonistic Mutant Pairs.

International journal of cancer·2026

Related Experiment Video

Updated: Mar 29, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.2K

CRISPR-Cas9-based target validation for p53-reactivating model compounds.

Michael Wanzel1,2, Jonas B Vischedyk1, Miriam P Gittler1

  • 1Institute of Molecular Oncology, Philipps University, Marburg, Germany.

Nature Chemical Biology
|November 24, 2015
PubMed
Summary
This summary is machine-generated.

Compounds targeting the p53-Mdm2 interaction show promise in cancer therapy. However, resistance mechanisms vary by drug, impacting treatment effectiveness and patient selection for p53-reactivating therapies.

More Related Videos

CRISPR/Cas9 Editing of the C. elegans rbm-3.2 Gene using the dpy-10 Co-CRISPR Screening Marker and Assembled Ribonucleoprotein Complexes.
07:46

CRISPR/Cas9 Editing of the C. elegans rbm-3.2 Gene using the dpy-10 Co-CRISPR Screening Marker and Assembled Ribonucleoprotein Complexes.

Published on: December 11, 2020

6.6K
A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization
08:20

A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization

Published on: September 2, 2021

4.7K

Related Experiment Videos

Last Updated: Mar 29, 2026

Yeast As a Chassis for Developing Functional Assays to Study Human P53
14:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

10.2K
CRISPR/Cas9 Editing of the C. elegans rbm-3.2 Gene using the dpy-10 Co-CRISPR Screening Marker and Assembled Ribonucleoprotein Complexes.
07:46

CRISPR/Cas9 Editing of the C. elegans rbm-3.2 Gene using the dpy-10 Co-CRISPR Screening Marker and Assembled Ribonucleoprotein Complexes.

Published on: December 11, 2020

6.6K
A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization
08:20

A New Toolkit for Evaluating Gene Functions using Conditional Cas9 Stabilization

Published on: September 2, 2021

4.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Genetics

Background:

  • Mdm2-mediated p53 inactivation is common in cancer, making p53-Mdm2 interaction inhibitors promising therapeutic agents.
  • Understanding resistance mechanisms to p53-reactivating drugs is crucial for effective cancer treatment.

Purpose of the Study:

  • To investigate compound-specific resistance mechanisms to p53-reactivating drugs.
  • To validate drug targets using CRISPR-Cas9 technology.
  • To determine patient allocation strategies for p53-reactivating therapies.

Main Methods:

  • CRISPR-Cas9-based target validation in lung and colorectal cancer cell lines.
  • Assessing cellular sensitivity to nutlin and RITA.
  • Evaluating DNA damage induction and repair pathways.
  • Utilizing RNA interference and pharmacological inhibitors (mTOR inhibitors) to target FancD2.

Main Results:

  • Nutlin's efficacy depends on functional p53, while RITA sensitivity correlates with DNA damage induction.
  • RITA-resistant cells exhibit cross-resistance to DNA crosslinking agents like cisplatin and enhanced DNA cross-link repair.
  • Inhibition of FancD2 restores RITA sensitivity in resistant cells.

Conclusions:

  • Resistance mechanisms to p53-reactivating compounds are drug-specific.
  • CRISPR-Cas9 is valuable for target validation and understanding resistance.
  • Patient selection for p53-reactivating therapies should consider these compound-specific resistance mechanisms.